Breast Cancer

Patients with acquired ESR1 mutations after disease progression and post-treatment for locally advanced or metastatic estrogen receptor–positive, HER2-negative breast cancer may benefit from treatment with lasofoxifene in combination with abemaciclib.

Results of a matching-adjusted indirect comparison study showed that patients with HR-positive/HER2–negative advanced breast cancer treated with ribociclib and an aromatase inhibitor were more likely to have better symptom-related quality of life than patients who received abemaciclib and an aromatase inhibitor.

Factors associated with early discontinuation of adjuvant abemaciclib for hormone receptor—positive, HER2-negative, node-positive high-risk early breast cancer inform future treatment monitoring.

Alpelisib combined with fulvestrant represents a viable treatment option for patients with hormone receptor–positive, HER2-negative advanced breast cancer, regardless of mutation status.

The phase 3 DESTINY-Breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with HER2-low, hormone receptor–positive metastatic breast cancer.

Patritumab deruxtecan induced positive efficacy, according to the phase 1/2 U31402-J101 trial in patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

At 2022 ASCO, final survival data from the phase 3 PALOMA-2 trial confirmed similar survival between palbociclib plus letrozole and letrozole alone.

Ribociclib plus endocrine therapy for hormone receptor–positive, HER2-negative advanced breast cancer following progression on a CDK4/6 inhibitor bests matched placebo.

Compared with chemotherapy, sacituzumab govitecan led to better progression-free survival outcomes in patients with hormone receptor–positive, HER2-negative breast cancer.

European patients with locally advanced or early-stage triple-negative breast cancer at high risk of recurrence can now receive treatment with neoadjuvant pembrolizumab and chemotherapy, as well as pembrolizumab monotherapy post surgery following its approval by the European Commission.

A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.

Using skin-sparing mastectomy and immediate deep inferior epigastric perforator flap reconstruction following preoperative radiotherapy was safe and feasible in patients with primary breast cancer.

A look at the evolving role of neurooncologists in the treatment of patients with HER2+ breast cancer and brain metastases and future perspectives in the management of this patient population.

Experts have a conversation of the use of trastuzumab deruxtecan therapy for patients with progressive brain metastases while weighing common toxicities and clinical trial data.

Program chair Aditya Bardia, MD, MPH, invites you to PER®’s complimentary in-person and virtual satellite symposium.

Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer may receive alternative treatment with switch maintenance endocrine therapy and bevacizumab and experience notable efficacy and improved safety vs continued weekly paclitaxel and bevacizumab.

Findings from a post-hoc analysis identified disparities in Black patients with early hormone receptor–positive breast cancer that could not be explained by early discontinuation of endocrine therapy, clinicopathologic characteristics, insurance coverage, or neighborhood deprivation index.

Breast cancer mortality could be reduced by half for patients with ATM, CHEK2, and PALB2 pathogenic variants who undergo annual MRI screenings between the ages of 30 to 35 years and annual MRI screenings and mammography for those 40 or older.

Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.

Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.

A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.

Sara Hurvitz, MD, presents the case of a 66-year-old woman with ER+ HER2+ invasive ductal carcinoma and brain metastases.

A look at exciting clinical trials enrolling patients with HER2+ breast cancer and leptomeningeal disease, a previously unheard-of opportunity.

Patients with node-positive breast cancer did not have a significant improvement in disease-free survival with the addition of internal mammary node irradiation to regional nodal irradiation; however, patients with medically or centrally located tumors could benefit.

Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.

An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.

A neuro-oncologist explains the prevalence of leptomeningeal metastases in HER2+ breast cancer and her preferred method of treatment.

Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.

Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.

Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.